Experts at ISC 2026 highlighted growing evidence that GLP-1 receptor agonists may reduce stroke risk and support brain health ...
Most VVD in clinical trials have been shown to exert anti-fibrotic effects – but findings are mixed around whether they also improve pulmonary function tests and prevent progression of SSc-associated ...
The progressive worsening of liver cirrhosis and portal hypertension (HTN) decreases intra-hepatic nitric oxide (NO), which is counterbalanced by increased NO secretion from adjacent endothelial cells ...
It is known that vasculopathy plays a pivotal role in the pathogenesis of systemic sclerosis (SSc). Vasoactive vasodilating drugs (VVD) are an option. The most recent treatment recommendations from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results